These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 8386135)

  • 1. Over-expression of C-myc increases the sensitivity of Epstein-Barr virus immortalized lymphoblastoid cells to non-MHC-restricted cytotoxicity.
    Cuomo L; Zhang QJ; Lombardi L; Torsteinsdottir S; Klein G; Dalla-Favera R; Masucci MG
    Int J Cancer; 1993 Apr; 53(6):1008-12. PubMed ID: 8386135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression.
    Rowe M; Khanna R; Jacob CA; Argaet V; Kelly A; Powis S; Belich M; Croom-Carter D; Lee S; Burrows SR
    Eur J Immunol; 1995 May; 25(5):1374-84. PubMed ID: 7774641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
    Torsteinsdottir S; Masucci MG; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
    Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5620-4. PubMed ID: 3016710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel strategy of c-myc oncogene in NK activity regulation not related to the W6/32 MHC class-I epitope.
    La Cava A; Carbone E; Moscarella A; Barcová M; Salzano S; Zappacosta S; Fontana S
    Int J Cancer; 1994 Jul; 58(1):123-8. PubMed ID: 7516924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
    Torsteinsdottir S; Cuomo L; Klein E; Masucci MG
    Cell Immunol; 1991 Oct; 137(2):501-13. PubMed ID: 1654213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
    Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class I major histocompatibility complex-restricted cytotoxic T lymphocytes specific for Epstein-Barr virus (EBV)-transformed B lymphoblastoid cell lines against which they were raised.
    Hill AB; Lee SP; Haurum JS; Murray N; Yao QY; Rowe M; Signoret N; Rickinson AB; McMichael AJ
    J Exp Med; 1995 Jun; 181(6):2221-8. PubMed ID: 7539044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of sublines selected for loss of HLA expression from an EBV-transformed lymphoblastoid cell line. Changes in sensitivity to cytotoxic T cells activated by allostimulation and natural killer cells activated by IFN or IL-2.
    Ohlén C; Bejarano MT; Grönberg A; Torsteinsdottir S; Franksson L; Ljunggren HG; Klein E; Klein G; Kärre K
    J Immunol; 1989 May; 142(9):3336-41. PubMed ID: 2468716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
    Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
    Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nonclassical major histocompatibility complex molecule Qa-2 protects tumor cells from NK cell- and lymphokine-activated killer cell-mediated cytolysis.
    Chiang EY; Henson M; Stroynowski I
    J Immunol; 2002 Mar; 168(5):2200-11. PubMed ID: 11859106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphokine-activated killer (LAK) cells discriminate between Epstein-Barr virus (EBV)-positive Burkitt's lymphoma cells.
    Misko IS; Schmidt C; Martin N; Moss DJ; Sculley TB; Burrows S; Burman KJ
    Int J Cancer; 1990 Sep; 46(3):399-404. PubMed ID: 2168343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune escape by Epstein-Barr virus (EBV) carrying Burkitt's lymphoma: in vitro reconstitution of sensitivity to EBV-specific cytotoxic T cells.
    Masucci MG; Zhang QJ; Gavioli R; De Campos-Lima PO; Murray RJ; Brooks J; Griffin H; Ploegh H; Rickinson AB
    Int Immunol; 1992 Nov; 4(11):1283-92. PubMed ID: 1282031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
    Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
    Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 cross-linking enhances the immunogenicity of Burkitt's-lymphoma cell lines.
    Frisan T; Donati D; Cervenak L; Wilson J; Masucci MG; Bejarano MT
    Int J Cancer; 1999 Dec; 83(6):772-9. PubMed ID: 10597194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
    Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
    Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD4+ T cell-induced differentiation of EBV-transformed lymphoblastoid cells is associated with diminished recognition by EBV-specific CD8+ cytotoxic T cells.
    Khanolkar A; Fu Z; Underwood LJ; Bondurant KL; Rochford R; Cannon MJ
    J Immunol; 2003 Mar; 170(6):3187-94. PubMed ID: 12626577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential recognition of tumor-derived and in vitro Epstein-Barr virus-transformed B-cell lines by fetal calf serum-specific T4-positive cytotoxic T-lymphocyte clones.
    Torsteinsdottir S; Masucci MG; Brautbar C; Lenoir G; Klein G; Klein E
    Cell Immunol; 1986 Apr; 98(2):453-66. PubMed ID: 3019570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfection of the c-myc oncogene into normal Epstein-Barr virus-harboring B cells results in new phenotypic and functional features resembling those of Burkitt lymphoma cells and normal centroblasts.
    Cutrona G; Ulivi M; Fais F; Roncella S; Ferrarini M
    J Exp Med; 1995 Feb; 181(2):699-711. PubMed ID: 7836923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
    Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
    Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.